HOME >> MEDICINE >> NEWS
New leukemia drug shows promise in overriding all Gleevec resistance

(PHILADELPHIA) Temple University researchers have developed a new drug that could potentially treat all forms of Gleevec-resistant chronic myelogenous leukemia (CML). Their work is published in this week's early edition of Proceedings of the National Academy of Sciences.

According to lead researcher, Prem Reddy, Ph.D., professor of biochemistry and Director of the Fels Institute for Cancer Research at Temple University School of Medicine, most patients with advanced CML, a rare but deadly form of cancer, typically develop resistance to Gleevec, the most successful treatment for CML to date, within a few years of starting the therapy.

CML is caused by the Philadelphia chromosome, an abnormality that produces a cancer protein called BCR-ABL. Gleevec works by binding to BCR-ABL and completely blocking its activity, thereby stopping cancer growth. When Gleevec came to market about four years ago, it was widely hailed as a miracle drug. For the first time, there was hope for this group of patients.

"Gleevec has been a remarkable success for the treatment of CML. However, a significant number of patients eventually develop resistance to it because their cancer cells are able to mutate and adapt," said Reddy.

Since discovering this phenomenon, scientists have sought new ways to prevent or overcome this resistance. Recently, two experimental drugs were found to be effective in circumventing some but not all forms of Gleevec resistance. Both, for instance, failed to block the activity of a mutant BCR-ABL, called T315I, which is one of the more predominant mutations seen in Gleevec-resistant patients.

Reddy and his research team sought instead to develop a drug that would circumvent all of the mutations and therefore all forms of resistance. They focused on other possible avenues to inhibit the actions of BCR-ABL. To do so, they targeted parts of the BCR-ABL protein that didn't appear to be mutating and adapting to Gleevec.
'"/>

Contact: Eryn Jelesiewicz
dobeck@temple.edu
215-707-0730
Temple University
24-Jan-2005


Page: 1 2

Related medicine news :

1. Both inherited traits and tumor mutations affect response to treatment of leukemia
2. Plant derivative attacks the roots of leukemia
3. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
4. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
5. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
6. Cord blood transplantation now a viable option for adult leukemia patients
7. Peptide vaccine can produce complete remission in myeloid leukemia patients
8. Methylphenidate improves attention, behavior of children surviving leukemia, brain tumors
9. Obesity linked to another cancer - leukemia in older women
10. Improved acute lymphoblastic leukemia treatment offers hope for eliminating irradiation
11. Blood transplants may be more harmful than bone marrow transplants in pediatric leukemia patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... N.J. (PRWEB) , ... August 31, 2020 , ... ... leading cloud-based business management solution for chiropractors, announced today the launch of its ... healthcare professionals can start running their virtual practice in under 90 seconds. ...
(Date:8/31/2020)... ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to put financial ... look for ways to trim the fat from our monthly expenses and put more into ... also important that you have a financial safety net in place in case something were ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. ... with persons with autism and other developmental disabilities, as well as supporting staff ... education, adolescents with autism, school consultation, and staff development. She joined the company ...
(Date:8/28/2020)... JACKSONVILLE, Fla. (PRWEB) , ... August 28, 2020 ... ... that Forcura’s Founder & CEO Craig Mandeville was named an Entrepreneur Of The ... The Year program honors entrepreneurial business leaders whose ambitions deliver innovation, growth and ...
(Date:8/28/2020)... ... August 28, 2020 , ... With in-person gluten-free ... to continue helping the specialty-diet community connect with great, gluten-free brands. At the ... enter giveaways, chat with brands & watch over 50 educational classes... all online ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... (PRWEB) , ... August 26, ... ... member of Eurofins BioPharma Services, Laboratory Testing division, expands its technology footprint ... suite of Flow Cytometry platforms available. With industry-leading biomarker solutions, complemented with ...
(Date:8/26/2020)... ... August 26, 2020 , ... As the U.S. struggles ... daily routine for preventing the Coronavirus. Wear a mask, keep your distance, wash your ... Dr. Denis Burkitt said it best in 1977, “How much better it is to ...
(Date:8/26/2020)... , ... August 26, 2020 , ... ... non-profit organization devoted to funding innovative lymphoma research and serving the lymphoma community ... Anniversary with a special virtual LRF Gala and Charity Auction on Wednesday, ...
Breaking Medicine Technology:
Cached News: